CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Effects of mirikizumab versus placebo on histologic inflammation evaluated by comprehensive assessment in 5 intestinal segments in a randomized controlled phase 3 trial of participants with Crohn’s disease
DOI 10.1055/s-0045-1810728
Bibliografische Angaben
Nachweis in CareLit
Autor:innenV Jairath, F Magro, G De Hertogh, B Feagan, N Harpaz, T Hisamatsu, G D’Haens, R Pai, M Protic, E Hon, C Owen, R Escobar, W Reinisch, B Siegmund
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2025
Jahrgang / SeitenJg. 63 · S. e420-e421
Kernaussage aus der Literatur
Abstract-Vorschau
Effects of mirikizumab versus placebo on histologic inflammation evaluated by comprehensive assessment in 5 intestinal segments in a randomized controlled phase 3 trial of participants with Crohn’s disease
Zitieren
Zitierempfehlung
V Jairath, F Magro, G De Hertogh, B Feagan, N Harpaz, T Hisamatsu, G D’Haens, R Pai, M Protic, E Hon, C Owen, R Escobar, W Reinisch, B Siegmund (2025) Effects of mirikizumab versus placebo on histologic inflammation evaluated by comprehensive assessment in 5 intestinal segments in a randomized controlled phase 3 trial of participants with Crohn’s disease. Zeitschrift für Gastroenterologie, 63 (08), e420-e421. https://doi.org/10.1055/s-0045-1810728
Mit CareLit weiterarbeiten